Contains Nonbinding Recommendations

Draft Guidance on Risperidone

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Risperidone

Form/Route: Tablet/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 1 mg
   Subjects: Normal healthy males and females, general population
   Additional Comments: Due to safety concerns, bioequivalence studies should be conducted using the 1 mg strength.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 1 mg
   Subjects: Normal healthy males and females, general population
   Additional comments: Please see comment above.

Analytes to measure: Risperidone in plasma

Bioequivalence based on (90% CI): Risperidone

Waiver request of in-vivo testing: 0.25 mg, 0.5 mg, 2 mg, 3 mg and 4 mg based on (i) acceptable bioequivalence studies on the 1 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Oct 2005; May 2007